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Machteld Oudshoorn,5 James Gajewski,6 Gregory A. Hale,7 John Horan,8 Minoo Battiwalla,9
Susana R. Marino,10 Michelle Setterholm,4 Olle Ringden,11 Carolyn Hurley,12
Neal Flomenberg,13 Claudio Anasetti,14 Marcelo Fernandez-Vina,15 Stephanie J. Lee1The association between HLA matching and outcome in unrelated-donor peripheral blood stem cell (PBSC)
transplantation has not yet been established. In the present study, a total of 1933 unrelated donor–recipient pairs
who underwent PBSC transplantation between 1999 and 2006 for acute myelogenous leukemia, acute lympho-
blastic leukemia, myelodysplastic syndrome, or chronicmyelogenous leukemia and received high-resolutionHLA
typing for HLA-A, -B, -C, -DRB1, -DQA1, and -DQB1 were included in the analysis. Outcomes were compared
betweenHLA-matched andHLA-mismatched pairs, adjusting for patient and transplant characteristics. Matching
for HLA-A, -B, -C, and -DRB1 alleles (8/8match) was associated with better survival at 1 year comparedwith 7/8
HLA-matched pairs (56% vs 47%). Using 8/8 HLA–matched patients as the baseline (n5 1243), HLA-C antigen
mismatches (n 5 189) were statistically significantly associated with lower leukemia-free survival (relative risk
[RR], 1.36; 95% confidence interval [CI], 1.13-1.64; P 5 .0010), and increased risk for mortality (RR, 1.41; 95%
CI, 1.16-1.70; P5 .0005), treatment-related mortality (RR, 1.61; 95% CI, 1.25-2.08; P5 .0002), and grade III-IV
graft-versus-host disease (RR, 1.98; 95% CI, 1.50-2.62; P\.0001). HLA-B antigen or allele mismatching was as-
sociated with an increased risk for acute GVHD grade III-IV. No statistically significant differences in outcome
were observed for HLA-C allele (n 5 61), HLA-A antigen/allele (n 5 136), HLA-DRB1 allele (n 5 39), or
HLA-DQ antigen/allele (n 5 114) mismatches compared with 8/8 HLA–matched pairs. HLA mismatch was
not associated with relapse or chronic GVHD. HLA-C antigen–mismatched unrelated PBSC donors were asso-
ciated with worse outcomes compared with 8/8 HLA–matched donors. The study’s limited power due to small
sample size precludes conclusions about other mismatches.
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Disease free survivalINTRODUCTION International Blood and Marrow Transplant ResearchUnrelated donors have provided a vital resource for
patients who do not have an HLA-matched relative.
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products are mismatched for one or more of the recip-
ient’s HLA loci. Previous NMDP/CIBMTR studies
evaluating the effects of HLA mismatch included
predominantly bone marrow (BM) recipients. Given
that the number of unrelated donor PBSC
transplantations in the NMDP registry has now
reached sufficient quantity for preliminary analysis,
the present study was designed to determine the associ-
ation of HLA mismatch in PBSC transplantation with
survival, relapse, graft-versus-host disease (GVHD),
and transplantation-related mortality (TRM).
Previous studies from theNMDP/CIBMTR in the
setting of BM transplantation have shown an asso-
ciation between HLA mismatch and with worse
outcomes [1,2]. In particular, single mismatches at
HLA-A, -B, -C, or DRB1 were associated with
increased risk for TRM and acute GVHD compared
with 8/8 HLA–matched pairs. Isolated HLA-DQ
mismatches did not appear to be detrimental. Reports
from the Fred Hutchinson Cancer Research Center
and the JapaneseMarrowDonor Program also support
the concept that disparities involving HLA class I
alleles are independent risk factors for acute GVHD,
TRM, and overall survival [3,4].
In the 1990s, collection of granulocyte-colony
stimulating factor (G-CSF)-mobilized PBSCs was
introduced as an alternative to BM donation for volun-
teer unrelated donors [5]. Advantages of PBSCs over
BM include more rapid engraftment of neutrophils
and platelets for patients and the ability to avoid the
operating room for donors and physicians. Retrospec-
tive studies have found similar rates of acute GVHD,
TRM, relapse, and survival with unrelated donor
PBSCs and BM, but an increased incidence of
extensive chronic GVHD with PBSCs [6].
Although PBSCs have supplanted BM as the most
common source of unrelated hematopoietic stem cells,
the impact of HLA mismatch on outcomes after unre-
lated PBSC transplantation has not yet been well
studied. The present study was undertaken to compare
the outcomes of HLA-mismatched compared with
HLA-matched unrelated donor transplantation using
PBSCs as the graft source. Identification of mis-
matched HLA loci associated with particularly poor
outcomes may help guide donor selection when an
8/8 HLA–matched donor is not available and alloge-
neic transplantation is recommended.
PATIENTS AND METHODS
Study Population
The study population included all patients reported
to the NMDP/CIBMTR registries who received an
unrelated PBSC transplant between 1999 and 2006 for
acute myelogenous leukemia (AML), acute lymphoblas-
tic leukemia (ALL), myelodysplastic syndrome (MDS),or chronic myelogenous leukemia (CML) for whom ret-
rospective high-resolution HLA typing results were
available for both patient and unrelated donor. Diseases
were categorized as early phase (acute leukemia in first
complete remission [CR1], CML in first chronic phase,
and MDS-refractory anemia [RA]), intermediate phase
(acute leukemia in second remission [CR2] and CML
in accelerated or second chronic phase), or advanced
phase (acute leukemia advanced beyond CR2 or not in
remission, CML in blast crisis, MDS-RA with excess
blasts [RAEB] or in transformation [RAEB-T]). Condi-
tioning regimens were defined as ‘‘myeloablative’’ if the
patient received total body irradiation (TBI) at a dose
.500 cGy if given as a single dose or.800 cGy if given
in fractions, received busulfan at a dose $9.5 mg/kg, or
received melphalan at a dose .150 mg/m2. All other
regimens were considered either reduced-intensity con-
ditioning (RIC)ornonmyeloablative (NM)conditioning
[7]. All patients received T cell–replete grafts.
All patients included in this study signed informed
consent for reporting of clinical information to the
NMDP/CIBMTR registries in accordance with the
Declaration of Helsinki. Twenty-seven (1.3%) of other-
wise eligible patients were excluded to account for lack
of consent to use the data of surviving patients or to
adjust for potential bias by excluding appropriately the
same percentage of deceased patients using a biased
coin randomization, with exclusion probabilities based
on characteristics associated with not providing consent
for use of the data in survivors.
HLATyping
High-resolution typing for HLA-A, -B, -C,
-DRB1, -DQA1, -DQB1, -DPA1, and -DPB1was per-
formed as described previously [1]. Low-resolution (se-
rologic or antigen level) disparities involved conversion
of the DNA-based typing to its lower-level serologic
equivalent, usually by collapsing the 4-digit typing
result back to its first 2 digits, with the exception of
a few HLA-B alleles that were mapped to their corre-
sponding serologic specificities. Antigen and allelemis-
matches at HLA-DRB1 were combined. Mismatches
at HLA-DQ were scored if there was disparity for
either the -DQA1 or the -DQB1 sequence, because
both -DQA1 and -DQB1 genes contribute to the
expression of a single heterodimericHLA-DQprotein.
HLA-DQA1 was not considered for determination
of antigen matching. Directional mismatches (graft-
vs-host or host-vs-graft) were considered appropriate
in the analysis ofGVHDand engraftment, as described
previously [8]. Mismatches at homozygous alleles were
considered single mismatches.
Biostatistical Methods
Probabilities formortality and leukemia-free survival
(LFS)were calculatedusing theKaplan-Meier estimator,
and survival curves were compared using the log-rank
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lative incidence function [9]. Death was considered
a competing risk for all of the endpoints exceptmortality
andLFS. Relapse also was considered a competing event
for TRM. Patients were censored if they underwent
a second HCT or were alive at last follow-up.
The association between number and type of HLA
mismatches was evaluated using separate multivariate
proportional hazards models, adjusting for significant
clinical covariates. Similar to the 2007 NMDP/
CIBMTR survey [2], this approach compares sub-
groups of HLA-mismatched pairs with 8/8-matched
pairs. A P value \.01 was considered statistically
significant because of multiple testing.
All models were tested for significant clinical
covariates including disease, disease stage, Karnofsky
performance score (KPS), or Lansky performance
score, patient race, patient age, GVHD prophylaxis,
conditioning regimen, donor age, donor–patient cyto-
megalovirus (CMV) serology, T cell depletion, use of
TBI, patient–donor sexmatch, and year of transplanta-
tion. Models were adjusted for any clinical factors that
were related to a given outcome at P\ .05. All vari-
ables were tested for affirmation of the proportional
hazards assumption and for interactions with HLA
matching. No significant interactions were identified.Table 1. Characteristics of 1933 Unrelated Donor PBSC
Transplant Recipients
Variable Number (%)
Age, years, median (range) 46 (<1-74)
Age group, n (%)
0-9 years 55 (3%)
10-19 years 119 (6%)
20-29 years 251 (13%)
30-39 years 276 (14%)
40-49 years 421 (22%)
50 and older 811 (42%)
Males, n (%) 1078 (56%)
KPS/Lansky Performance
Score $90, n (%)
1163 (66%)
Disease, n (%)
AML 946 (49%)
ALL 359 (19%)
CML 218 (11%)
MDS 410 (21%)
Disease stage, n (%)
Early 682 (35%)
Intermediate 453 (24%)
Advanced (late) 798 (41%)
Conditioning regimen, n (%)
Myeloablative 1260 (65%)
RIC/NM 673 (35%)
Year of HCT, n (%)
1999-2002 395 (20%)
2003-2006 1538 (80%)
Median follow-up of survivors,
months, median (range)
24 (3-89)RESULTS
Patient and Transplant Characteristics
Characteristics of the study population are shown
in Table 1. Themedian follow-up duration was 2 years
(range, 0.3-7.4 years).
HLA-DQ and -DP Mismatch
HLA-DQ mismatch was not statistically associ-
ated with survival in patients otherwise matched for
HLA-A, -B, -C, and -DRB1. The relative risk (RR)
for mortality for single -DQ allele (n 5 68) or antigen
(n 5 46) mismatch was 0.97 (95% confidence interval
[CI], 0.71-1.34; P5 .87) and 1.35 (95% CI, 0.95-1.96;
P5 .10), respectively, compared with a full match (n5
1125). Because there were no statistically significant
differences in LFS, relapse, TRM, and acute and
chronic GVHD, HLA-DQmismatching was not con-
sidered further in the determination of HLA-matching
status. Information on HLA-DP matching was avail-
able in only 20% of donor–recipient pairs, too few to
be sufficient for analysis; accordingly, HLA-DP mis-
match was not considered in the subsequent analyses.
Number and Type of HLA Mismatches
Table 2 shows the association between 1 or 2 allele
and/or antigen mismatches and the transplantation
outcomes evaluated. HLA-mismatched pairs thatcontained at least 1 antigen mismatch had statistically
worse survival and disease-free survival than pairs who
were 8/8 matched; however, survival of 7/8 allele
mismatches was not statistically different than 8/8
matched pairs. Among 6/8-matched pairs, 29 pairs with
double-allele mismatches did not have worse survival
than 8/8-matched pairs (RR, 1.21; 95% CI, 0.77-1.90;
P 5 .42), but the small number of patients limited the
power of this analysis. The 6/8-matched pairs that had
at least 1 antigen mismatch had statistically worse
survival than the 8/8-matched pairs.
For TRM, any degree of HLA mismatch was asso-
ciated with worse outcome. In contrast, HLA mis-
match was not associated with a lower risk of relapse.
Grade III-IV acute GVHDwas increased with any de-
gree of HLA mismatch (Table 2). There was no asso-
ciation between number and type of HLA mismatches
and grade II-IV acute GVHD or chronic GVHD.
Locus-Specific HLA Mismatch
Table 3 presents the results of locus-specific analysis
of single mismatched pairs for the outcomes of interest.
Note that the power of this analysis is limited for some
subgroups because of small sample sizes.Thus, although
evidence of a statistically significant worse outcome can
be accepted, the absence of such a finding does not
mean that a mismatch is ‘‘safe.’’ Mismatch of a single
HLA-C antigen was associated with a statistically signif-
icantly higher risk for mortality, TRM, and grade III-IV
acute GVHD and lower LFS. At 2 years, unadjusted
888 Biol Blood Marrow Transplant 17:885-892, 2011A. Woolfrey et al.survival was 32% for HLA-C mismatches, compared
with44%for8/8matches (P5 .003);LFSwas26%com-
paredwith 40%(P5 .0002); and cumulative incidenceof
TRM was 40% compared with 28% (P 5 .002). Mis-
match at a single HLA-B allele or antigen was also asso-
ciated with increased risk of grade III-IV acute GVHD.
The risks of relapse and chronic GVHD were not
statistically different for 8/8 matches compared with
any locus-specific mismatch, including HLA-C
antigen–mismatched pairs.
Myeloablative versus Nonmyeloablative
Conditioning
Table 4 compares HLA-C antigen–mismatched
pairs, other 7/8 antigen (non-C)– mismatched pairs,
7/8 allele–mismatched pairs, and 8/8-matched pairs
by conditioning regimen intensity. HLA-C antigen
mismatch is associated with an increased risk of mor-
tality compared with 8/8 matches for patients given
either myeloablative conditioning (n 5 122; RR,
1.40; 95% CI, 1.10-1.78; P 5 .006) or nonmyeloabla-
tive conditioning or RIC (n 5 65; RR, 1.40; 95% CI,
1.01-1.95; P5 .04). In contrast, other 7/8 (non-C) an-
tigen–mismatched pairs and 7/8 allele–mismatched
pairs did not have statistically higher mortalityTable 2. Effect of the Number of Mismatched HLA Antigens or Al
PBSC Transplants, Adjusted for Patient and Transplant Characteris
n
Mortality
8/8 match 1243
One allele mismatch 208
One antigen mismatch 293
Two allele/antigen mismatch 99
TRM
8/8 match 1243
One allele mismatch 208
One antigen mismatch 293
Two allele/antigen mismatch 99
LFS
8/8 match 1243
One allele mismatch 208
One antigen mismatch 293
Two allele/antigen mismatch 99
Relapse
8/8 match 1243
One allele mismatch 208
One antigen mismatch 293
Two allele/antigen mismatch 99
Acute GVHD II-IV
8/8 match 1243
One allele mismatch 208
One antigen mismatch 266
Two allele/antigen mismatch 97
Acute GVHD III-IV
8/8 match 1243
One allele mismatch 208
One antigen mismatch 266
Two allele/antigen mismatch 97
Chronic GVHD
8/8 match 1243
One allele mismatch 208
One antigen mismatch 266
Two allele/antigen mismatch 97compared with 8/8-matched pairs in either the mye-
loablative or nonmyeloablative/RIC group.
Mismatched PBSC Compared with Mismatched
Marrow
To gain insight into whether using BM instead of
PBSC would be advantageous when the use of an
HLA-mismatched donor is planned, we compared the
PBSC recipients in our research dataset with the recipi-
ents of BM grafts in the analysis reported by Lee et al.
[2]. No statistically significant differences in mortality
were seen when HLA-mismatched transplantations
were performed with PBSC or with BM. The risk for
mortality at 1 year did not differ between recipients of
7/8 antigen–mismatched BMgrafts (n5 547) and recip-
ients of 7/8 antigen–mismatched PBSC grafts (n5 293)
(RR, 1.13; 95% CI, 0.93-1.40; P5 .26), or between the
subgroups of BM (n 5 321) and PBSC (n 5 187)
recipients when the mismatch involved a single
HLA-C antigen (RR, 1.08; 95% CI, 0.84-1.70; P 5
.55).These results,which are adjusted for disease, disease
status, and KPS pretransplantation, suggest there is no
advantage to changing the graft source from PBSC to
BM when using a HLA-mismatched donor even if the
antigen mismatch is at HLA-C. Year of transplantationleles on Mortality and Relapse among Recipients of Unrelated
tics
RR 95% CI P
1.00
1.11 0.91-1.35 .30
1.32 1.12-1.55 .0007
2.32 1.78-3.02 <.0001
1.00
1.41 1.09-1.81 .008
1.54 1.24-1.91 .0001
3.16 2.28-4.37 <.0001
1.00
1.15 0.95-1.38 .15
1.29 1.10-1.51 .0013
2.25 1.74-2.92 <.0001
1.00
0.90 0.68-1.20 .48
1.04 0.82-1.32 .76
1.24 0.78-1.98 .36
1.00
0.93 0.93-1.37 .24
1.21 1.02-1.43 .03
1.18 0.85-1.64 .31
1.00
1.59 1.20-2.09 .0012
1.93 1.53-2.44 <.0001
2.43 1.64-3.59 <.0001
1.00
1.00 0.81-1.23 .97
1.15 0.95-1.40 .14
1.03 0.69-1.54 .88
Table 3. Effect of the Locus of Mismatched HLA Antigens or Alleles on Mortality, Relapse, and GVHD among Recipients of
Unrelated PBSC Transplants, Adjusted for Patient and Transplant Characteristics
n RR 95% CI P
Mortality
8/8 match 1243 1.00
HLA-A allele mismatch 51 1.16 0.80-1.67 .43
HLA-A antigen mismatch 85 1.17 0.88-1.55 .29
HLA-A allele or antigen mismatch* 136 1.17 0.93-1.47 .19
HLA-B allele mismatch 57 1.29 0.92-1.82 .14
HLA-B antigen mismatch 16 1.01 0.50-2.04 .97
HLA-B allele or antigen mismatch* 73 1.22 0.90-1.67 .19
HLA-C allele mismatch 61 0.82 0.57-1.19 .30
HLA-C antigen mismatch 189 1.41 1.16-1.70 .0005
HLA-DRB1 mismatch 39 1.30 0.87-1.94 .20
TRM
8/8 match 1243 1.00
HLA-A allele mismatch 51 1.47 0.92-2.35 .11
HLA-A antigen mismatch 85 1.33 0.91-1.93 .14
HLA-A allele or antigen mismatch* 136 1.37 1.01-1.86 .04
HLA-B allele mismatch 57 1.75 1.14-2.69 .01
HLA-B antigen mismatch 16 1.65 0.81-3.38 .17
HLA-B allele or antigen mismatch* 73 1.74 1.20-2.51 .004
HLA-C allele mismatch 61 1.02 0.62-1.67 .93
HLA-C antigen mismatch 189 1.61 1.25-2.08 .0002
HLA-DRB1 mismatch 39 1.53 0.94-2.51 .09
LFS
8/8 match 1243 1.00
HLA-A allele mismatch 51 1.20 0.84-1.71 .31
HLA-A antigen mismatch 85 1.11 0.84-1.48 .46
HLA-A allele or antigen mismatch* 136 1.15 0.91-1.44 .24
HLA-B allele mismatch 57 1.28 0.93-1.77 .13
HLA-B antigen mismatch 16 1.20 0.64-2.26 .57
HLA-B allele or antigen mismatch* 73 1.27 0.95-1.69 .12
HLA-C allele mismatch 61 0.92 0.65-1.30 .62
HLA-C antigen mismatch 189 1.36 1.13-1.64 .001
HLA-DRB1 mismatch 39 1.27 0.86-1.87 .22
Relapse
8/8 match 1243 1.00
HLA-A allele mismatch 51 0.91 0.53-1.56 .73
HLA-A antigen mismatch 85 0.97 0.62-1.52 .90
HLA-A allele or antigen mismatch* 136 0.95 0.67-1.36 .79
HLA-B allele mismatch 57 1.03 0.62-1.71 .91
HLA-B antigen mismatch 16 0.42 0.10-1.74 .23
HLA-B allele or antigen mismatch* 73 0.89 0.55-1.44 .64
HLA-C allele mismatch 61 0.80 0.48-1.32 .38
HLA-C antigen mismatch 189 1.09 0.83-1.44 .53
HLA-DRB1 mismatch 39 0.91 0.48-1.72 .77
GVHD grade II-IV
8/8 match 1279 1.00
HLA-A allele mismatch 54 0.99 0.67-1.44 .93
HLA-A antigen mismatch 79 1.33 1.00-1.77 .05
HLA-A allele or antigen mismatch* 136 1.18 0.94-1.50 .16
HLA-B allele mismatch 56 0.99 0.69-1.44 .97
HLA-B antigen mismatch 16 1.51 0.85-2.69 .16
HLA-B allele or antigen mismatch* 73 1.11 0.81-1.52 .52
HLA-C allele mismatch 64 1.16 0.83-1.62 .40
HLA-C antigen mismatch 168 1.12 0.90-1.39 .30
HLA-DRB1 mismatch 34 1.60 1.06-1.80 .03
GVHD grade III-IV
8/8 match 1279 1.00
HLA-A allele mismatch 54 1.38 0.81-2.37 .24
HLA-A antigen mismatch 79 1.54 1.01-2.34 .04
HLA-A allele or antigen mismatch* 136 1.46 1.04-2.06 .03
HLA-B allele mismatch 56 1.91 1.21-3.02 .006
HLA-B antigen mismatch 16 3.25 1.66-6.36 .0006
HLA-B allele or antigen mismatch* 73 2.22 1.51-3.25 <.0001
HLA-C allele mismatch 64 1.17 0.69-1.97 .56
HLA-C antigen mismatch 168 1.98 1.50-2.62 <.0001
HLA-DRB1 mismatch 34 1.87 1.05-3.35 .03
Chronic GVHD
8/8 match 1279 1.00
HLA-A allele mismatch 54 0.99 0.68-1.45 .97
(Continued )
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Table 3. (Continued )
n RR 95% CI P
HLA-A antigen mismatch 79 1.24 0.90-1.69 .19
HLA-A allele or antigen mismatch* 136 1.12 0.87-1.43 .38
HLA-B allele mismatch 56 0.87 0.56-1.36 .55
HLA-B antigen mismatch 16 1.14 0.59-2.22 .69
HLA-B allele or antigen mismatch* 73 0.94 0.64-1.36 .73
HLA-C allele mismatch 64 1.03 0.73-1.45 .86
HLA-C antigen mismatch 168 1.12 0.88-1.42 .35
HLA-DRB1 mismatch 34 1.11 0.68-1.84 .67
*From a separate model in which allele and antigen mismatches were combined for the A and B loci.
890 Biol Blood Marrow Transplant 17:885-892, 2011A. Woolfrey et al.and intensityof the conditioning regimenwerenot found
to be statistically significant in these models.DISCUSSION
This study of HLA matching and outcomes of
unrelated-donor PBSC transplantation shows that
HLA mismatching in general, and HLA-C antigen
and HLA-B allele and antigen mismatching in partic-
ular, are associated with statistically worse outcomes
compared with 8/8 HLA matching. No statistically
significant associations between HLA mismatching
and relapse or chronic GVHD were observed. Mis-
matching at HLA-DQwas not associated with statisti-
cally significantly worse outcomes and thus was
disregarded when determining HLA matching. Over-
all, our findings are similar to those from previous
studies of the effects of HLA mismatching in BM
transplantation in largely Caucasian cohorts [1,2].
Most of the patients included in the previously
reported sequential retrospective studies of high-
resolution HLA matching received BM grafts. Com-
pared with BM, PBSCs contain 10-fold more CD31
cells and 4-fold more CD341 cells on average [10].
The relative contribution of cell subsets also differ;
for example, PBSCs have a 3-fold higher CD3:CD
34 ratio and a 25-fold higher CD14:CD34 ratio
than BM, as well as a greater proportion of CD4 cells
with an anti-inflammatory (Th2) phenotype [11-14].
Other studies have indicated relatively more DC2
dendritic cells and skewing of the DC1:DC2 ratio to
DC2 cells within PBSCs [14]. All PBSC donors receive
G-CSF, whereas most unrelated BM donors do not.
The differences in cellular characteristics of the twoTable 4. Association of 7/8 HLA-C Antigen Mismatch with Mortali
Regimen
Myeloablative
n RR* 95% CI
8/8 796 1.00
7/8 HLA-C antigen 122 1.40 1.10-1.78
7/8 other antigen 80 1.23 0.91-1.66
7/8 allele 130 1.14 0.88-1.47
*Adjusted for disease and KPS; stratified by disease status and GVHD prophyproducts suggest, at a minimum, that the effect of
HLA mismatching shown for BM transplants cannot
be assumed to be applicable to PBSC products.
Although our results do not define an ‘‘optimal’’mis-
match for a PBSC transplant, they clearly show that an
HLA-C antigen mismatch is associated with lower sur-
vival and higher TRM in both the single- and double-
mismatch settings. This conclusion is consistent with
findings of Flomenburg et al. [1] and Lee et al. [2]. In
the study of Lee et al. [2], HLA-C antigen mismatch
(RR, 1.22; 95%CI 1.06-1.39; P5.004), HLA-A antigen
mismatch (RR, 1.24; 95% CI, 1.02-1.52; P\.001), and
HLA-DRB1 allele mismatch (RR, 1.42; 95% CI,
1.13-1.80; P5 .003) were associated with worse survival
compared with the 8/8match.Our study of PBSC trans-
plantation also found a statistically significant relation-
ship between HLA-B mismatch and increased risk for
grade III-IV acute GVHD, but no association with sur-
vival. It is notable that the higher rates of severe acute
GVHD observed in HLA-C antigen and HLA-B anti-
gen and allele–mismatched pairs did not translate into
higher chronic GVHD rates or lower relapse rates. We
hypothesize that this could possibly be due to the higher
TRM generally associated with grade III-IV acute
GVHD, the fact that chronic GVHD is more closely
linked with prevention of relapse, or our small sample
size, which limited the study’s power.
The main limitation of the present study is the
small number of observations in some of the sub-
groups, which might have led to erroneous estimation
of the effect of a specific HLA mismatch and limited
power in comparisons. In addition, the median
follow-up period of 2 years is relatively short compared
with that in previous studies of HLA matching in BMty in Patients Conditioned with a Myeloablative or an RIC/NM
RIC/NM
P n RR* 95% CI P
447 1.00
.006 65 1.40 1.01-1.95 .04
.18 26 0.93 0.54-1.61 .80
.32 78 .82 0.82-1.55 .45
laxis.
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35% of our study population, but represent approxi-
mately 50% of the procedures currently performed.
As the number of PBSC transplants increases and
follow-up lengthens, a subsequent analysis will be im-
portant to update our observations and to consider
other factors that could possibly affect outcomes,
such as killer Ig-like receptor (KIR) status [15-19] or
HLA-DP matching [19,20]. For example, in the BM
setting, the earlier study of Flomenberg et al. [1]
(n 5 1874) did not find an increased risk associated
with single allele mismatches [1], whereas the larger
Lee et al. study (n 5 3857) found an association be-
tween a single allele or antigen mismatch and adverse
outcomes [2].
Neither of these previous BM studies included
substantial numbers of NM or RIC transplants, which
typically use PBSC grafts. A reasonable concern with
these conditioning regimens is that rejection of a mis-
matched graft or risk for relapse may be amplified be-
cause host T or natural killer (NK) cells might survive
less-intensive conditioning. Our analysis showed that
HLA-C antigen mismatch is associated with higher
risk for overall mortality andTRM, but not relapse, af-
ter NM/RIC PBSC HCT, similar to that for myeloa-
blative HCT (relapse data not shown). Unfortunately,
we lack data on KIR genotyping to allow a refined
analysis of possible NK cell effects.
In cases when HLA-C antigen mismatching cannot
be avoided, onemight wonder whether a BMgraftmight
be better tolerated than a PBSC graft. Our exploratory
analysis found no advantage to using BM as the cell
source from a donor with an isolated HLA-C antigen
mismatch. We caution that the present retrospective
analysis cannot take into consideration all factors that
might introduce bias. Our presentation of these results
is intended not to address the question of whether one
graft source ispreferableover theother, but rather topro-
vide the best available data pending larger studies. In an
analysis by Eapen et al. [21], outcomes of 7/8-matched
BM and 7/8-matched PBSC transplantations appeared
to be similar, although direct comparisons were not per-
formed and locus-specific data were not provided. In
October 2009, the Blood andMarrow Transplant Clini-
cal Trials Network finished enrollment of a 550-patient
prospective multicenter randomized trial to assess
the risks and benefits of BM versus PBSCs from unre-
lated donors. A planned subgroup analysis of HLA-
mismatched grafts has been included in the study
design, the results of which will be important for
addressing the issues raised in our analysis.
It is important to remember that our results are not
meant to imply that an HLA-mismatched graft should
not be used, only that the greater risks compared
with 8/8 HLA–matched grafts should be recognized
when present. For many patients, the best hope forlong-term LFS will remain allogeneic HCT, even
with a less-than-optimal donor.ACKNOWLEDGMENTS
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